IMVT
Immunovant Inc.
$24.68
-$0.14(-0.56%)
62
Overall
55
Value
100
Tech
31
Quality
Market Cap
$3.83B
Volume
2.72M
52W Range
$12.72 - $32.10
Target Price
$38.33
Order:
Income Statement
| Metric | Trend | Chart | 2020 Mar | 2021 Mar | 2022 Mar | 2023 Mar | 2024 Mar | 2025 Mar |
|---|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $66.1M | $108.1M | $156.0M | $208.3M | $282.7M | $438.2M | ||
| Research & Development | $47.9M | $68.6M | $101.8M | $170.3M | $225.4M | $360.9M | ||
| Research Expense | $47.9M | $68.6M | $101.8M | $160.3M | $212.9M | $360.9M | ||
| Selling, General & Administrative | $18.2M | $39.5M | $54.2M | $48.0M | $57.3M | $77.2M | ||
| General & Administrative Expenses | $18.2M | $39.5M | $54.2M | $48.0M | $57.3M | $77.2M | ||
| Salaries & Wages | $-6.8M | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | $1.3M | $500.0K | -- | -- | -- | ||
| OPERATING INCOME | ||||||||
| Operating income | $-66.1M | $-108.1M | $-156.0M | $-218.3M | $-282.7M | $-438.2M | ||
| EBITDA | $-65.6M | $-108.1M | $-155.9M | $-217.2M | $-282.4M | $-437.2M | ||
| NON-OPERATING ITEMS | ||||||||
| Interest Expense (Non-Operating) | $625.0K | -- | -- | $-7.6M | $-24.9M | $-24.7M | ||
| Net Non-Operating Interest Income/Expense | $-625.0K | -- | -- | $7.6M | $24.9M | $24.7M | ||
| Other Income/Expense | $-412.0K | $-328.0K | $-781.0K | $-10.3M | $1.0M | $-471.0K | ||
| Other Special Charges | $412.0K | $328.0K | $-781.0K | $-253.0K | $-1.0M | $471.0K | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-65.7M | $-108.1M | $-156.0M | $-218.5M | $-283.7M | $-437.7M | ||
| Pre-Tax Income | $-66.3M | $-107.8M | $-156.8M | $-211.0M | $-258.8M | $-412.9M | ||
| INCOME TAX | ||||||||
| Tax Provision | $97.0K | $-358.0K | $-84.0K | $9.0K | $567.0K | $891.0K | ||
| NET INCOME | ||||||||
| Net Income | $-66.4M | $-107.4M | $-156.7M | $-211.0M | $-259.3M | $-413.8M | ||
| Net Income (Continuing Operations) | $-66.4M | $-107.4M | $-156.7M | $-211.0M | $-259.3M | $-413.8M | ||
| Net Income (Discontinued Operations) | $-66.4M | $-107.4M | $-156.7M | $-211.0M | $-259.3M | $-413.8M | ||
| Net Income (Common Stockholders) | $-66.4M | $-107.4M | $-156.7M | $-211.0M | $-259.3M | $-413.8M | ||
| Normalized Income | -- | -- | $-156.9M | -- | -- | $-408.8M | ||
| TOTALS | ||||||||
| Total Expenses | $66.1M | $108.1M | $156.0M | $208.3M | $282.7M | $438.2M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $43.2M | $87.8M | $109.7M | $123.1M | $138.1M | $151.6M | ||
| Average Shares Outstanding (Diluted) | $43.2M | $87.8M | $109.7M | $123.1M | $138.1M | $151.6M | ||
| Shares Outstanding | $81.8M | $98.0M | $116.5M | $130.4M | $174.3M | $170.9M | ||
| Basic EPS | -- | $-1.22 | $-1.43 | $-1.71 | $-1.88 | $-2.73 | ||
| Basic EPS (Continuing Operations) | -- | $-1.22 | $-1.43 | $-1.71 | $-1.88 | $-2.73 | ||
| Diluted EPS | $-1.54 | $-1.22 | $-1.43 | $-1.71 | $-1.88 | $-2.73 | ||
| Diluted EPS (Continuing Operations) | $-1.54 | -- | $-1.43 | $-1.71 | $-1.88 | $-2.73 | ||
| OTHER METRICS | ||||||||
| Development Expense | -- | -- | -- | $10.0M | $12.5M | -- | ||
| Other Gand A | $18.2M | $39.5M | $54.2M | $48.0M | $57.3M | $77.2M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMVT | $24.68 | -0.6% | 2.72M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |